Free cash flow remained negative in every quarter, reaching -$34.8M in 2026Q2 with operating cash outflow at 1.93 times net loss, suggesting cash burn is outpacing accounting losses and no dividends or buybacks offset the drain.
ALX Oncology Holdings Inc. (ALXO) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -68.42M | -84.14M | -121.91M | -130.36M | -89.22M | -68.1M | -38.29M | -14.25M | -13.19M |
| Operating CF Margin % | - | - | - | - | - | - | -3239.34% | -297.1% | -638.12% |
| Operating CF Growth % | 110.33% | 30.98% | 6.48% | -46.11% | -31.02% | -77.86% | -168.71% | -8.03% | - |
| Net Income | -80.57M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Depreciation & Amortization | 443K | 706K | 872K | 836K | 342K | 51K | 202K | 429K | 431K |
| Stock-Based Compensation | 10.79M | 12.58M | 27.09M | 26.27M | 23.84M | 13.91M | 5.44M | 297K | 269K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 174K | 3.93M | -2.6M | -4.96M | 228K | 5.42M | 1.57M | 11K | 0 |
| Working Capital Changes | 739K | 336K | -12.43M | 8.3M | 9.85M | -4.03M | 247K | 4.26M | -159K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 536K | 396K | -932K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.59M | 421K | -4.02M | 458K | 4.51M | 3.29M | -3.74M | 2.98M | -269K |
| Cash from Investing | -68.04M | 82.59M | 86.26M | 44.66M | -235.42M | -4.92M | 610K | -353K | -653K |
| Capital Expenditures | -181K | -212K | -447K | -1.27M | -1.43M | -666K | -31K | -353K | -653K |
| CapEx % of Revenue | - | - | - | - | - | - | 2.62% | 7.36% | 31.59% |
| Acquisitions | 0 | 0 | 0 | 0 | 233.99K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 173K | 0 | 0 | 0 | -233.99K | -4.26M | 641K | 0 | 0 |
| Cash from Financing | 148.61M | 362K | 30.82M | 59.29M | 9.86M | 2.47M | 462.88M | 15.36M | 1K |
| Debt Issued (Net) | -1.99M | -1.36M | -827K | -388K | 9.61M | -281K | 0 | 5.92M | 0 |
| Equity Issued (Net) | 142.65M | 1.73M | 31.64M | 58.89M | 903K | 2.75M | 472.94M | 9.43M | -6K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 31K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K |
| Other Financing | 7.95M | 0 | 0 | 792K | -655K | 0 | -10.05M | 10K | 7K |
| Net Change in Cash | 12.14M | -1.19M | -4.84M | -26.42M | -314.78M | -70.55M | 425.2M | 755K | -13.84M |
| Free Cash Flow | -68.61M | -84.35M | -122.36M | -131.64M | -90.65M | -73.02M | -38.32M | -14.6M | -13.84M |
| FCF Margin % | - | - | - | - | - | - | -3241.96% | -304.46% | -669.71% |
| FCF Growth % | 29.59% | 31.06% | 7.05% | -45.22% | -24.14% | -90.56% | -162.43% | -5.48% | - |
| FCF per Share | -0.49 | -1.57 | -2.35 | -3.06 | -2.23 | -1.81 | -0.96 | -0.67 | -0.63 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.83x | 0.90x | 0.81x | 0.72x | 0.82x | 0.84x | 0.74x | 0.96x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 11K | 427K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 274K | 47K | 0 | 0 |
Quick answers to the most common questions about buying ALXO stock.
ALX Oncology Holdings Inc. (ALXO) generated $-84.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
ALX Oncology Holdings Inc. (ALXO) reported negative free cash flow of $84.4M in 2025, indicating capital requirements exceeded cash from operations.
ALX Oncology Holdings Inc. (ALXO) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Continued cash burn dependence
Metrics are mathematically derived from official filings.
Operating Cash Burn Exceeds Reported Losses
According to ALXO's reported quarterly figures, operating cash outflow exceeded the net loss in several recent periods, with the ratio reaching 1.93 in 2026Q2, suggesting cash consumption is running ahead of accounting losses and warrants close monitoring.
In most quarters the ratio of operating cash flow to net income sits between 0.67 and 1.10, meaning the company burned slightly less cash than its accounting loss in some periods and more in others. The 2026Q2 spike to roughly 1.93 times the net loss, driven by a $34.7M operating outflow against an $18.0M net loss, is the most important data point and implies a substantial working capital or non-cash timing effect that the supplied data does not fully explain. Investors should monitor whether this divergence persists, since it would indicate the true cash runway is shorter than earnings alone suggest.
Free Cash Flow Deficit Narrowing Unevenly
Based on ALXO's reported figures, free cash flow remained negative in every quarter, improving from roughly -$38.1M in 2024Q1 to -$18.7M in 2026Q1 before worsening to -$34.8M in 2026Q2.
Because revenue is effectively absent, free cash flow margin is not meaningful and the analysis rests on absolute burn rates. The trend shows a clear reduction in quarterly burn over the two-year window, which aligns with the prior income statement finding of lower R&D spending. However, the 2026Q2 reversal to a burn near the 2024 peak suggests the improvement has not been linear and that quarterly volatility in working capital is material to the runway estimate.
Minimal Capital Intensity Confirms Asset-Light Model
As reported in financial statements, ALXO's capital expenditures remained below $150K in every quarter shown, with the largest outlay of $149.0K in 2024Q3, indicating a very light fixed-asset footprint.
Capital spending is negligible relative to operating cash outflows, so maintenance versus growth capex distinction carries little analytical weight for this company. Depreciation and amortization of roughly $150K to $240K per quarter is similarly small, consistent with a clinical-stage model that outsources manufacturing and trials. The implication is that cash burn is driven almost entirely by operating expenses rather than physical investment.
No Shareholder Returns, Dependence on External Funding
Based on ALXO's reported data, the company paid no dividends and conducted no share buybacks in any of the ten quarters, leaving external capital markets as the apparent source of funding for ongoing burn.
The absence of dividends and repurchases is expected for a pre-revenue biotechnology company and does not itself signal distress. The more relevant question is how the cumulative operating outflow exceeding $200M over this period has been financed, which the supplied cash flow data does not disclose. Investors should review the balance sheet and financing disclosures to assess remaining liquidity and the likelihood of future equity dilution.
Stock Compensation Masks True Cash Economics
According to reported figures, stock-based compensation of $2.1M to $7.3M per quarter is added back in operating cash flow, meaning the reported cash burn may understate the economic cost of employee equity pay.
Because SBC is a non-cash charge, it lowers net income without consuming cash, which can make the net loss appear larger than the cash burn in some periods. Here the operating cash outflow still exceeded the net loss in several quarters, so SBC does not fully explain the gap. Investors should recognize that continued equity compensation implies shareholder dilution, which represents a real economic cost not captured in the free cash flow figure.